All In Biotech

Drug Trial Radar · NCT06863701

Efficacy Anda Safety of Etoricoxib With Betamethasone for the Treatment of Acute Gout Arthritis

Efficacy and Safety Study for the Combination of Etoricoxib / Betamethasone Compared to Etoricoxib for the Treatment of Patients Diagnosed With Acute Gout Arthritis

Last checked: Nov 20, 2026Latest source record: Apr 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

72

Planned (sponsor's estimate)

Start

Jan 27, 2025

Primary completion

Dec 31, 2026

Study completion Jan 31, 2027

Sponsor

Sponsor type
Industry
First posted
Mar 7, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase III longitudinal, multicenter, randomized, double-blind clinical trial. The aim of this study is to evaluate the efficacy and safety of the Fixed-Dose Combination of Etoricoxib/Betamethasone Versus Etoricoxib in Patients With Acute Gouty Arthritis

Conditions

  • Gout Arthritis
  • Gout Attack

Interventions

  • Etoricoxib + Betamethasone fixed doseDrug

    One tablet of 90 mg / 0.25 mg a day

  • Etoricoxib fixed doseDrug

    One pill of 90 mg a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Compare the degree of pain in the affected joint (using the Likert pain scale) on days 2, 5, and 8, according to their baseline measurement in each treatment group.Time frame: 8 days
  2. Number of participants with treatment-related adverse events through the patient's diary record.Time frame: 8 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Laboratorio Silanes, S.A. de C.V.

    Mexico City, Mexico · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.